DBV Technologies S.A. Form 6-K Summary
Business Context and Reporting Period
DBV Technologies S.A., a clinical-stage specialty biopharmaceutical company, reported interim financial results for the first half of 2015 (January 1 to June 30, 2015). The company focuses on developing Viaskin, a platform for treating food allergies (specifically milk and peanut) via skin administration. The financial statements were subject to a limited review by statutory auditors.
Key Financial Metrics (H1 2015 vs. H1 2014)
| Metric (in millions EUR) | H1 2015 | H1 2014 |
|---|---|---|
| Total Revenues | 3.17 | 2.66 |
| R&D Expenses | (12.50) | (10.44) |
| G&A Expenses | (5.49) | (4.18) |
| Operating Loss | (14.92) | (12.08) |
| Net Loss | (14.48) | (11.77) |
| EPS (EUR) | (0.74) | (0.77) |
| Net Cash Flow from Operating Activities | (12.44) | (10.47) |
| Net Cash Flow from Financing Activities | 3.18 | 0.75 |
| Net Cash Flow | (10.07) | (10.34) |
| Cash Position (End of Period) | 104.53 | 29.06 |
Material Changes
- Revenue Growth: Total revenues increased by approximately 19% to €3.17 million, driven primarily by government research tax credits and subsidies. Sales of the diagnostic product Diallertest increased slightly to €107,520, though the company does not anticipate material future revenue from this product.
- Expense Increases: R&D expenses rose 20% to €12.50 million due to increased pre-clinical and clinical activity and hiring. G&A expenses increased 31% to €5.49 million, attributed to administrative growth and professional fees associated with becoming a U.S. registered public company in October 2014.
- Liquidity Improvement: The cash position grew significantly from €29.06 million to €104.53 million, primarily due to net cash inflows from financing activities (€3.18 million) driven by the exercise of equity instruments.
- Loss Per Share: While the net loss increased in absolute terms, the loss per share improved slightly from €(0.77) to €(0.74) due to the weighted average number of shares outstanding.
Outlook, Risks, and Management Commentary
- Future Results: The company expects to announce nine-month topline results and cash position on November 3, 2015.
- Strategic Focus: Management remains focused on the Viaskin platform for food allergies. The Viaskin Peanut program has received Fast Track and Breakthrough Therapy designations from the FDA for children.
- Risks: The filing includes standard forward-looking statement disclaimers, noting that future performance involves substantial risks and uncertainties. Investors are cautioned not to place undue reliance on these statements.
Investor Verification Checklist
- Verify the sustainability of government research tax credits and subsidies, which constitute the majority of current revenue.
- Confirm the timeline and milestones for the Viaskin Peanut and Viaskin Milk clinical trials.
- Monitor the burn rate relative to the €104.53 million cash position to assess runway for future operations.
- Review the impact of U.S. regulatory compliance costs on future G&A expenses.